Erenumab for the Treatment of Episodic Migraine

Achal Patel, Mercer University College of Pharmacy

It is reported that migraines are the third most prevalent illness in the world, prominently affecting women. [1] Symptoms include visual disturbances, extreme sensitivity to sound, light, touch, and smell, and tingling or numbness in the extremities and face. [1] Migraines can be classified as either episodic (< 15 headache days/month) or chronic (≤ 15 headache days/month). [2]

Erenumab is a fully human monoclonal antibody that inhibits the calcitonin gene-related peptide (CGRP) receptor that is involved in migraine pathophysiology through nociceptive mechanisms in the trigeminovascular system. [3] In a prior phase two trial, erenumab has shown a reduction in the number of episodic migraines at monthly doses of 70 mg and 140 mg. [3]

Continue reading


Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Hiral Patel, PharmD. Candidate 2015, Mercer University College of Pharmacy

According to the US National Library of Medicine, the gene proprotein convertase subtilisin/kexin type 9 (PCSK9) appears to control the number of low-density lipoprotein (LDL) receptors which determines how quickly cholesterol is removed from the bloodstream.1

Alirocumab, a monoclonal antibody that inhibits PCSK9, has been shown to reduce LDL cholesterol levels in patients who are receiving statin therapy. In a phase two study, alirocumab in combination with atorvastatin for 12 weeks reduced LDL levels by 40 – 72%.2 However, longer term data on safety and efficacy of alirocumab are needed.

Continue reading